Skip to main content

Advertisement

SpringerLink
Log in

Clinicopathological features of thirty patients with primary breast lymphoma and review of the literature

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Primary breast lymphoma (PBL) is a rare disease accounting for 0.4–0.5 % of all breast malignancies. Accumulating evidence indicates that the diagnosis, prognostic factors, and optimal management of PBL are difficult. The present study aims to investigate the clinicopathological features and optimal treatment of PBL and to evaluate the institutional experience in this patient population. A total of 30 patients with PBL from January 2002 to December 2012 treated in He’nan Province Tumor Hospital were selected. The patients’ clinical and pathological characteristics, treatment and response data, patterns of recurrence, and outcomes were retrospectively analyzed, and the relevant literatures were reviewed. All the cases were female, and the median age was 45. Diffuse large B cell lymphoma was the most common histological subtype seen in 23 of 30 patients. With a median follow-up time 32 months, median OS was 42 months (95 % CI 25–58 months), with 5-year OS rates 48 % (95 % CI 36–59 %). The median PFS was 14 months (95 % CI 6–30 months), with 5-year PFS rates 32 % (95 % CI 20–45 %). The prognostic factors that retained statistical significance for OS were IPI (P < 0.001), age (P = 0.04), and stage (P < 0.001). For PFS, significant prognostic factors were IPI (P = 0.01), radiotherapy given (P = 0.02) and stage (P = 0.02). PBL appears to have a worse prognosis. The present treatment method for PBL is a comprehensive way of diagnostic surgery together with radiotherapy and chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jeanneret-Sozzi W, Taghian A, Epelbaum R, et al. Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study. BMC Cancer. 2008;8:86.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol. 2008;19(2):233–41.

    Article  CAS  PubMed  Google Scholar 

  3. Aviles A, Delgado S, Nambo MJ, et al. Primary breast lymphoma: results of a controlled clinical trial. Oncology. 2005;69(3):256–60.

    Article  PubMed  Google Scholar 

  4. Domchek SM, Hecht JL, Fleming MD, et al. Lymphomas of the breast: primary and secondary involvement. Cancer. 2002;94(1):6–13.

    Article  PubMed  Google Scholar 

  5. Caon J, Wai ES, Hart J, et al. Treatment and outcomes of primary breast lymphoma. Clin Breast Cancer. 2012;12(6):412–9.

    Article  PubMed  Google Scholar 

  6. Surov A, Holzhausen HJ, Wienke A, et al. Primary and secondary breast lymphoma: prevalence, clinical signs and radiological features. Br J Radiol. 2012;85(1014):e195–205.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Wiseman C, Liao KT. Primary lymphoma of the breast. Cancer. 1972;29(6):1705–12.

    Article  CAS  PubMed  Google Scholar 

  8. Hugh JC, Jackson FI, Hanson J, et al. Primary breast lymphoma. An immunohistologic study of 20 new cases. Cancer. 1990;66(12):2602–11.

    Article  CAS  PubMed  Google Scholar 

  9. Joks M, Mysliwiec K, Lewandowski K. Primary breast lymphoma—a review of the literature and report of three cases. Arch Med Sci. 2011;7(1):27–33.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Brogi E, Harris NL. Lymphomas of the breast: pathology and clinical behavior. Semin Oncol. 1999;26(3):357–64.

    CAS  PubMed  Google Scholar 

  11. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31(11):1860–1.

    CAS  PubMed  Google Scholar 

  12. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997. Mod Pathol. 2000;13(2):193–207.

    Article  CAS  PubMed  Google Scholar 

  13. Validire P, Capovilla M, Asselain B, et al. Primary breast non-Hodgkin’s lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors. Am J Hematol. 2009;84(3):133–9.

    Article  PubMed  Google Scholar 

  14. Hosein PJ, Maragulia JC, Salzberg MP, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2014;165(3):358–63.

    Article  CAS  PubMed  Google Scholar 

  15. Sabate JM, Gomez A, Torrubia S, et al. Lymphoma of the breast: clinical and radiologic features with pathologic correlation in 28 patients. Breast J. 2002;8(5):294–304.

    Article  CAS  PubMed  Google Scholar 

  16. Meroni S, Moscovici OC, Rahal D, et al. Synchronous bilateral primary breast lymphoma. Breast J. 2012;18(4):378–9.

    Article  PubMed  Google Scholar 

  17. Zygogianni AG, Kokkakis J, Antypas C, et al. Bilateral primary breast Burkitt’s lymphoma. Breast J. 2010;16(6):655–6.

    Article  PubMed  Google Scholar 

  18. Mildon KH, Ansell P, Roman E, et al. Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, diffuse large B-cell and follicular lymphomas: a UK case-control study. Cancer Causes Control. 2010;21(12):2079–83.

    Article  PubMed  Google Scholar 

  19. Fernandez E, Gallus S, Bosetti C, et al. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer. 2003;105(3):408–12.

    Article  CAS  PubMed  Google Scholar 

  20. Teras LR, Patel AV, Hildebrand JS, et al. Postmenopausal unopposed estrogen and estrogen plus progestin use and risk of non-Hodgkin lymphoma in the American Cancer Society Cancer Prevention Study-II Cohort. Leuk Lymphoma. 2013;54(4):720–5.

    Article  CAS  PubMed  Google Scholar 

  21. Aviv A, Tadmor T, Polliack A. Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. Ann Oncol. 2013;24(9):2236–44.

    Article  CAS  PubMed  Google Scholar 

  22. Yoshida S, Nakamura N, Sasaki Y, et al. Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Mod Pathol. 2005;18(3):398–405.

    Article  CAS  PubMed  Google Scholar 

  23. Ganjoo K, Advani R, Mariappan MR, et al. Non-Hodgkin lymphoma of the breast. Cancer. 2007;110(1):25–30.

    Article  PubMed  Google Scholar 

  24. Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110(1):29–36.

    Article  CAS  PubMed  Google Scholar 

  25. Calvo-Villas JM, Martin A, Conde E, et al. Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation. Ann Oncol. 2010;21(9):1891–7.

    Article  CAS  PubMed  Google Scholar 

  26. Lin Y, Guo XM, Shen KW, et al. Primary breast lymphoma: long-term treatment outcome and prognosis. Leuk Lymphoma. 2006;47(10):2102–9.

    Article  PubMed  Google Scholar 

  27. Guo HY, Zhao XM, Li J, et al. Primary non-Hodgkin’s lymphoma of the breast: eight-year follow-up experience. Int J Hematol. 2008;87(5):491–7.

    Article  PubMed  Google Scholar 

  28. Yhim HY, Kim JS, Kang HJ, et al. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. Int J Cancer. 2012;131(1):235–43.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Breast Oncology, The Affiliated Cancer Hospital of Zhengzhou University, 127 Dongming Road, Zhengzhou, 450008, China

    Y. B. Shao, X. F. Sun, Y. N. He, C. J. Liu & H. Liu

  2. He’nan Province Tumor Hospital, Zhengzhou, China

    Y. B. Shao, X. F. Sun, Y. N. He, C. J. Liu & H. Liu

Authors
  1. Y. B. Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X. F. Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. N. He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. J. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Liu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shao, Y.B., Sun, X.F., He, Y.N. et al. Clinicopathological features of thirty patients with primary breast lymphoma and review of the literature. Med Oncol 32, 5 (2015). https://doi.org/10.1007/s12032-014-0448-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0448-z

Keywords

Search

Navigation